Arrowhead Pharma (ARWR) Stock Price, Quote & News

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, t...

Industry: Biotechnology

Sector: Healthcare

Phone: 626 304 3400

Fax: 626 304 3401

Website: arrowheadpharma.com

Address:

177 East Colorado Boulevard, Suite 700, Pasadena, United States

EmC_Invests Feb. 3 at 8:20 PM

$ARWR biotech base forming quiet accumulation possible

0 · Reply

johnnygogogo Feb. 3 at 6:24 PM

$ARWR instead of Waldo, they should release a book called “Where’s VWAP?”

0 · Reply

LeftyT Feb. 3 at 5:18 PM

$ARWR Just added at 70.97 for the next algo bump.

0 · Reply

LeftyT Feb. 3 at 5:15 PM

$ARWR It looks like the lying media is teaming up with the lying salesmen to slow down the Arrowhead train. The Motley Fools put out a piece on Privium Fund reducing their position by 75,747 shares in Q4, valued at $3.71 M like it was a negative. They failed to highlight that Privium's position was up in value by $13.8 M during the quarter, and they were just rebalancing a bit with their sale and still holding w/ upside bias expectations. Silly Fools... I pity the Fools. To their credit, they did highlight that ARWR "Skyrocketed 290% in One Year", so maybe they have some integrity. :)

1 · Reply

skeezbag Feb. 3 at 3:57 PM

$ARWR we have not been granted approval by the lying salesmen to be a mid cap

1 · Reply

LeftyT Feb. 3 at 3:37 PM

$ARWR Added at 72.19 on the dip. Looks like the daily $2 algo swings are back in vogue these days so I'll pick up extra shares to play the algo games for pocket money again.

1 · Reply

BiodegradableBurger Feb. 3 at 3:31 PM

$ARWR 2nd time this hit $76 and the engine made a total reverse. First time was on 6 Jan when we released ARO-INHBE data.

0 · Reply

skeezbag Feb. 3 at 3:24 PM

$ARWR discord should learn to count. There was not 8 1 share 1604 trades

0 · Reply

skeezbag Feb. 3 at 2:54 PM

$ARWR market is fake anyone who disagrees will now be known as a Bill

0 · Reply

BiodegradableBurger Feb. 3 at 2:52 PM

$ARWR Holy smokes Bioman, what the f happened we were up $2 now 10c. Lol!

0 · Reply

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Jan 20, 2026, 4:30 PM EST - 14 days ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

Jan 12, 2026, 2:06 PM EST - 22 days ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 7, 2026, 11:05 PM EST - 26 days ago

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

Jan 7, 2026, 7:30 AM EST - 27 days ago

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Jan 6, 2026, 6:14 PM EST - 4 weeks ago

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Jan 6, 2026, 3:18 PM EST - 4 weeks ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript

Jan 6, 2026, 2:58 PM EST - 4 weeks ago

Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update

Jan 6, 2026, 11:26 AM EST - 4 weeks ago

Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay.

Jan 6, 2026, 10:32 AM EST - 4 weeks ago

Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials

Jan 6, 2026, 7:30 AM EST - 4 weeks ago

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

Jan 5, 2026, 7:30 AM EST - 4 weeks ago

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Dec 23, 2025, 7:30 AM EST - 6 weeks ago

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

Dec 15, 2025, 4:30 PM EST - 7 weeks ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Dec 8, 2025, 7:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Dec 2, 2025, 7:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Dec 1, 2025, 4:00 PM EST - 2 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Nov 27, 2025, 7:43 PM EST - 2 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript

Nov 25, 2025, 11:43 PM EST - 2 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript

Nov 25, 2025, 4:00 PM EST - 2 months ago

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Nov 24, 2025, 7:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

SRPT

Nov 19, 2025, 3:48 AM EST - 2 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript

Nov 18, 2025, 11:54 PM EST - 2 months ago

Arrowhead Is A Buy On REDEMPLO(TM) Approval And Strong Cash Runway

Nov 18, 2025, 11:52 AM EST - 2 months ago

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Nov 18, 2025, 11:21 AM EST - 2 months ago

US FDA approves Arrowhead's genetic disorder drug

Nov 17, 2025, 10:08 AM EST - 2 months ago

Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead

Nov 6, 2025, 4:30 PM EST - 3 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Nov 4, 2025, 7:30 AM EST - 3 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Oct 21, 2025, 7:30 AM EDT - 3 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Oct 7, 2025, 7:30 AM EDT - 4 months ago

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Sep 29, 2025, 7:11 AM EDT - 4 months ago

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ASMB ATRA CORT

Sep 11, 2025, 7:30 AM EDT - 5 months ago

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Sep 10, 2025, 2:55 PM EDT - 5 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 7:30 AM EDT - 5 months ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Sep 9, 2025, 1:42 PM EDT - 5 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 7, 2025, 9:35 PM EDT - 5 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 3, 2025, 4:00 PM EDT - 5 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Citi's 2025 Biopharma Back To School Conference (Transcript)

Sep 3, 2025, 1:15 PM EDT - 5 months ago

Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place

Sep 2, 2025, 8:13 AM EDT - 5 months ago

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

NVS

Sep 2, 2025, 7:30 AM EDT - 5 months ago

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Aug 27, 2025, 7:30 AM EDT - 5 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Aug 13, 2025, 4:10 PM EDT - 6 months ago

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Aug 8, 2025, 8:48 PM EDT - 6 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript

Aug 7, 2025, 4:01 PM EDT - 6 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Aug 1, 2025, 6:30 AM EDT - 6 months ago

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Jul 28, 2025, 7:30 AM EDT - 6 months ago

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

SRPT

Jul 23, 2025, 8:00 AM EDT - 6 months ago

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

Jul 22, 2025, 1:30 PM EDT - 7 months ago

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

SRPT

Jul 21, 2025, 4:01 PM EDT - 7 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

Jul 8, 2025, 7:30 AM EDT - 7 months ago

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

EmC_Invests Feb. 3 at 8:20 PM

$ARWR biotech base forming quiet accumulation possible

0 · Reply

johnnygogogo Feb. 3 at 6:24 PM

$ARWR instead of Waldo, they should release a book called “Where’s VWAP?”

0 · Reply

LeftyT Feb. 3 at 5:18 PM

$ARWR Just added at 70.97 for the next algo bump.

0 · Reply

LeftyT Feb. 3 at 5:15 PM

1 · Reply

skeezbag Feb. 3 at 3:57 PM

$ARWR we have not been granted approval by the lying salesmen to be a mid cap

1 · Reply

LeftyT Feb. 3 at 3:37 PM

$ARWR Added at 72.19 on the dip. Looks like the daily $2 algo swings are back in vogue these days so I'll pick up extra shares to play the algo games for pocket money again.

1 · Reply

BiodegradableBurger Feb. 3 at 3:31 PM

$ARWR 2nd time this hit $76 and the engine made a total reverse. First time was on 6 Jan when we released ARO-INHBE data.

0 · Reply

skeezbag Feb. 3 at 3:24 PM

$ARWR discord should learn to count. There was not 8 1 share 1604 trades

0 · Reply

skeezbag Feb. 3 at 2:54 PM

$ARWR market is fake anyone who disagrees will now be known as a Bill

0 · Reply

BiodegradableBurger Feb. 3 at 2:52 PM

$ARWR Holy smokes Bioman, what the f happened we were up $2 now 10c. Lol!

0 · Reply

CDMO Feb. 3 at 2:34 PM

$ARWR 75

1 · Reply

StockConsultant Feb. 3 at 2:26 PM

$ARWR Arrowhead Pharmaceuticals stock with a narrow range breakout

0 · Reply

aliliimr Feb. 3 at 11:44 AM

$ARWR

0 · Reply

Food4Thought Feb. 3 at 6:31 AM

$ARWR This is how to stay relevant in pipeline. Recruiting for 14 in various phases. https://clinicaltrials.gov/search?term=arrowhead%20pharmaceutical&aggFilters=status:rec

0 · Reply

Night_Owl_Biotech Feb. 3 at 12:55 AM

The attached table notes the day of the week all 82 commercial-stage oncology (26) & non-oncology (56) bio M&A transactions were announced (those bios with 1st FDA approvals since 1/1/2013 so you won't see SGEN nor CELG for example). Roughly half of these M&A exits are announced on Mondays. In oncology its 62% of the time. Wednesday is the next most popular day of the week to announce acquisitions in this peer group. We track the dates M&A transactions are announced manually & use the "WEEKDAY" tool in excel to extrapolate the day of the week. In the past, we misread the "WEEKDAY" result by assuming 2 represented Tuesdays. Hence until we re-ran this analysis we thought Tuesdays were the most popular day to announce M&A trxs. We're going to run the same for clinical-stage bio M&A exits in the next few days. Our educated guesses of strong M&A candidates include: $SNDX $ARWR $CYTK $VKTX $XERS This is not investment advice. We're only sharing our analysis for entertainment purposes only.

0 · Reply

CDMO Feb. 2 at 7:06 PM

$ARWR interesting that roche is also very interested in RNA interference... https://www.sanegenebio.com/sanegenebio-announces-rnai-global-licensing-collaboration-with-genentech/

2 · Reply

Synaptric Feb. 2 at 4:37 PM

$ARWR Much to like on the Arrowhead chart. Mark Nov 21 as the beginning of the current move with a MACD crossover and bounce off the 50-day. Consider the healthy RSI since staying above 50. As price is now approaching the 50-day again, consider a good close today with mark another MACD crossover. With that in mind, taking out that pesky January 6th island shooting star looks doable. If that succeeds, the next logical move from a fib extension is in the low 90s.

0 · Reply

Lraifinance Feb. 2 at 3:41 PM

$ARWR ☕️

0 · Reply

skeezbag Feb. 2 at 2:55 PM

$ARWR today is all about keeping macd in check Fake fucking market

1 · Reply

skeezbag Jan. 31 at 1:00 PM

$ARWR 81% short volume yesterday. Fake fucking market

0 · Reply

Jschwarma Jan. 30 at 9:09 PM

$ARWR what kind of horseshit was that the last 5 mins down a buck

2 · Reply

ChessGM Jan. 30 at 8:05 PM

$ARWR https://youtu.be/h-s8MagQo1k. My focus list for stocks reporting earnings next week.

0 · Reply

Market Cap	9.71B
Revenue (ttm)	829.45M
Net Income (ttm)	-1.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-0.20%
Debt to Equity Ratio	0.51

Volume	2,348,300
Avg Vol	2,890,292
Day's Range	N/A - N/A
Shares Out	140.01M
Stochastic %K	95%
Beta	1.21
Analysts	Strong Sell
Price Target	$80.00